Linked Life Data

18926757

Source:http://linkedlifedata.com/resource/pubmed/id/18926757

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6 Pt 1
pubmed:dateCreated
2008-12-8
pubmed:abstractText
Diabetic nephropathy is the leading cause of end-stage kidney disease in developed countries and is related to chronic hyperglycaemia. The increased production and tissue deposition of advanced glycation end products (AGE) are known to play a major role in the pathogenesis of diabetic kidney damage. This study was undertaken to determine if lysozyme (LZ), microencapsulated in orally administrable chitosan-coated alginate microspheres (MS), is effective against the early changes seen in the initial stages of diabetic nephropathy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1262-3636
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
587-94
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy.
pubmed:affiliation
Callerio Foundation-Onlus, Institutes of Biological Researches, via Alexander Fleming 22631, 34127 Trieste, Italy. m.cocchietto@callerio.org
pubmed:publicationType
Journal Article